Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions
You may also be interested in...
Medicare “Phases In” Changes To Claims Appeals Process, Starting In May
At least four Medicare-contracted entities will provide a second level of appeals for beneficiaries seeking to overturn claims redeterminations that carriers issue after December
Medicare “Phases In” Changes To Claims Appeals Process, Starting In May
At least four Medicare-contracted entities will provide a second level of appeals for beneficiaries seeking to overturn claims redeterminations that carriers issue after December
Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members